The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab

被引:0
作者
Francesca Di Fabio
Carmine Pinto
Fabiola L. Rojas Llimpe
Stefano Fanti
Paolo Castellucci
Ciro Longobardi
Vita Mutri
Chiara Funaioli
Francesca Sperandi
Stefania Giaquinta
Andrea A. Martoni
机构
[1] S. Orsola-Malpighi Hospital,Medical Oncology Unit
[2] S. Orsola-Malpighi Hospital,Nuclear Medicine Unit
来源
Gastric Cancer | 2007年 / 10卷
关键词
PET; Advanced gastric adenocarcinoma; Cetuximab;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:221 / 227
页数:6
相关论文
共 128 条
[1]  
Kamangar F(2006)Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world J Clin Oncol 24 2137-50
[2]  
Dores GM(1999)Survival in stomach cancer is improving: results of a nationwide population-based Swedish study Ann Surg 230 162-9
[3]  
Anderson WF(2003)Gastric cancer epidemiology and risk factors J Clin Epidemiol 56 1-9
[4]  
Hansson LE(2006)Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data J Clin Oncol 24 2903-9
[5]  
Sparen P(2006)Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma J Clin Oncol 24 5201-6
[6]  
Nyren O(2007)Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX Study) Ann Oncol 18 510-7
[7]  
Kelley JR(2004)Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer World J Surg 28 247-53
[8]  
Duggan JM(2006)Staging and follow-up of gastrointestinal tumors with PET/CT Abdom Imaging 31 25-35
[9]  
Wagner AD(2006)Assessment of lymph node metastases using 18F-FDG PET in patients with advanced gastric cancer Eur J Nucl Med Mol Imaging 33 148-55
[10]  
Grothe W(2003)18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma J Nucl Med 44 224-39